Trial Profile
A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Flexible-Dose Study Evaluating the Effect of Lu AA21004 vs Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder Experiencing Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Vortioxetine (Primary) ; Escitalopram
- Indications Major depressive disorder; Sexual function disorders
- Focus Registrational; Therapeutic Use
- Sponsors Takeda
- 22 Oct 2018 According to a Takeda media release, the U.S. Food and Drug Administration has approved a supplemental new drug application (sNDA) for TRINTELLIX (vortioxetine).The TRINTELLIX U.S. labeling now includes data from this study that demonstrated superiority to a commonly-used selective serotonin reuptake inhibitor (SSRI), Lexapro (escitalopram) in improving treatment-emergent sexual dysfunction (TESD).
- 20 May 2015 Results presented at the 168th Annual Meeting of the American Psychiatric Association.
- 21 Oct 2014 Primary endpoint (Change in Sexual Functioning Questionnaire Short-Form (CSFQ-14) Total Score at Week 8) has been met according to results presented at the 27th Annual Congress of the European College of Neuropsychopharmacology.